Zydus Beats Garda with $166 Million All-Cash Takeover of Assertio
Zydus will buy Assertio for $166.4M, paying $23.50/share, giving shareholders more value and taking the company private.
/ 111 items
#XY Event-Driven Stocks↓
Insider Buying Sends Pulse Biosciences Stock Higher
Pulse Biosciences stock jumped after top executives bought $13M in shares, signaling strong confidence in future growth.
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
MacroGenics sells manufacturing site to Bora for $122.5M, keeps access, gains cash, and focuses on cancer drug development.
Rigel Pharmaceuticals Lands Exclusive Global Deal for Breakthrough Breast Cancer Drug Veppanu
Arvinas & Pfizer partner with Rigel to launch Veppanu, a new oral breast cancer drug showing strong results and better survival.
Alpha Tau Reports Breakthrough Interim Results in Brain Cancer Trial: 100% Disease Control and 67% Complete Response
Alpha Tau’s brain cancer trial shows 2/3 glioblastoma patients’ tumors disappeared, all controlled, with good safety so far.
MBX Biosciences Just Took a Big Step Toward Monthly Obesity Injections
MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment.